Skip to content
Laboratory measurement of extended half-life FIX
Satellite Symposium 2018
Speaker
Titel
S. Tiefenbacher
Laboratory measurement of extended half-life FVIII
Abstract not available!
The presentation is provided below.
Related items
Analytical Information :
3
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
1
Haemophilia B and treatment, case study
ECAT Documents :
26
Intrinsic Pathway of Coagulation
Hemophilia B
Factor IX Concentrates
Factor IX (FIX)
Extrinsic Pathway of Coagulation
Coumarin
Coagulation Factors
Bethesda Inhibitor Assay (Titer)
Performance of factor IX extended half-life product measurements in external quality control assessment programs
The performance of FVIII and FIX measurement in ECAT surveys
Laboratory assays for the measurement of Factor VIII and IX
Gene therapy, the future in hemophilia treatment?
The role of molecular biology in the diagnosis of impaired haemostasis
How to measure low levels of Factor VIII and IX
Introduction on Inhibitor Testing
Haemophilia, new development in patient treatment
Quality Assurance of extended half-life products
Potency labelling of extended half-life FVIII en FIX products
Treatmentof patients with extended half-life FVIII and FIX products
One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients
Haemophilia treatment and laboratory testing
New developments in haemophilia treatment
Hemophilia and gene therapy
When Haemostasis Assays Mislead
Guidance for FVIII/FIX Inhibitor testing
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors
Guidelines :
1
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Haemostatic Cascade :
6
TF Pathway (Extrinsic) with Common Pathway (PT)
Intrinsic Pathway APTT
Coagulation Pathways (All Components)
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
3
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
Quality Assurance of replacement therapy and future perspectives
External quality assessment for Factor VIII and Factor IX
Surveys and Studies :
3
Emicizumab pilot study, part II
Emicizumab pilot study, part I
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Questions or suggestions?
Clotpedia Support Form
Submit
Success
